The CXCR4 antagonist AMD3100 mobilizes a more primitive subset of CD34+cells than G-CSF

被引：0
|
作者：
Seeger, T
Veldwijk, M
Bridger, G
Calandra, G
Goldschmidt, H
Ho, A
Fruehauf, S
机构：
[1] Univ Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[2] German Canc Res Ctr, Dept E0120, D-6900 Heidelberg, Germany
[3] AnorMED, Langley, BC, Canada
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1969.1969
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1969
引用
收藏
页码：558A / 558A
页数：1
相关论文
共 50 条
  • [31] Insights into the biology of mobilized cells through innovative treatment schedules of the CXCR4 antagonist AMD3100
    Bonig, Halvard
    Papayannopoulou, Thalia
    BLOOD, 2007, 110 (11) : 661A - 661A
  • [32] Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
    Nervi, Bruno
    Ramirez, Pablo
    Rettig, Michael P.
    Uy, Geoffrey L.
    Holt, Matthew S.
    Ritchey, Julie K.
    Prior, Julie L.
    Piwnica-Worms, David
    Bridger, Gary
    Ley, Timothy J.
    DiPersio, John F.
    BLOOD, 2009, 113 (24) : 6206 - 6214
  • [33] The chemokine receptor CXCR4 antagonist AMD3100 exerts deleterious effects in endotoxemia in vivo
    Seemann, S.
    Lupp, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S64 - S65
  • [34] In vitro and preclinical activity of the novel AMD3100 CXCR4 antagonist in lymphoma models.
    Paul, S
    Mancuso, P
    Rabascio, C
    Gobbi, A
    Capillo, M
    Pruneri, G
    Martinelli, G
    Fricker, S
    Bridger, G
    Bertolini, F
    BLOOD, 2002, 100 (11) : 579A - 579A
  • [35] AMD3100 and G-CSF mobilize angiogenic cells into the blood of healthy donors.
    Shepherd, RM
    Capoccia, BJ
    Devine, SM
    Ingram, DA
    Link, DC
    BLOOD, 2005, 106 (11) : 846A - 846A
  • [36] Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4
    Fricker, Simon P.
    Anastassov, Virginia
    Cox, Jennifer
    Darkes, Marilyn C.
    Grujic, Ognjen
    Idzan, Stefan R.
    Labrecque, Jean
    Lau, Gloria
    Mosi, Renee M.
    Nelson, Kim L.
    Qin, Ling
    Santucci, Zeffy
    Wong, Rebecca S. Y.
    BIOCHEMICAL PHARMACOLOGY, 2006, 72 (05) : 588 - 596
  • [37] CD34+cells mobilized with the new CXCR4 antagonist AMD3100+G-CSF show increased anti-apoptotic, cell cycle, DNA repair and cell motility-associated gene expression when compared to G-CSF mobilization alone.
    Seeger, T
    Maier, P
    Li, L
    Laufs, S
    Eckstein, V
    Bridger, G
    Calandra, G
    Wenz, F
    Goldschmidt, H
    Ho, AD
    Fruehauf, S
    BLOOD, 2005, 106 (11) : 147B - 147B
  • [38] CD34+cells mobilized with the new CXCR4 antagonist AMD3100+G-CSF show increased anti-apoptotic, cell cycle, DNA repair and cell motility-associated gene expression when compared to G-CSF mobilization alone.
    Fruehauf, S.
    Seeger, T.
    Maier, P.
    Li, L.
    Laufs, S.
    Bridger, G.
    Calandra, G.
    Wenz, F.
    Wenz, F.
    Goldschmidt, H.
    Ho, A. D.
    CYTOTHERAPY, 2006, 8
  • [39] Suprasynergistic peripheral blood stem cell mobilization in normal and fanconi anemia knockout mice by the combination of G-CSF plus the CXCR4 antagonist AMD3100 and the CXCR2 agonist GROβ.
    Pelus, Louis M.
    Clapp, D. Wade
    Bridger, Gary
    BLOOD, 2006, 108 (11) : 909A - 909A
  • [40] Interference of the SDF-1/CXCR4 axis in mice with AMD3100 induces rapid high level mobilization of hematopoietic progenitor cells, and AMD3100 acts synergistically with G-CSF and MIP-1α to mobilize progenitors.
    Broxmeyer, HE
    Hangoc, G
    Cooper, S
    Bridger, G
    BLOOD, 2001, 98 (11) : 811A - 811A
12345